{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:03:14Z","timestamp":1771261394159,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:p>\n                    This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep infiltrating endometriosis (DIE). This study was a single-center retrospective cohort analysis. A total of 501 consecutive patients with endometriosis diagnosed and treated in our hospital from January 2023 to January 2024 were enrolled and divided into the OMA group (n\u2005=\u2005276), SUP group (n\u2005=\u2005125), and DIE group (n\u2005=\u2005100) based on imaging\/surgical phenotypes. All patients received monotherapy with DNG (2\u2009mg\/day) for at least 6 months. Differences in pain visual analog scale (VAS) scores, lesion size, serum CA125 levels, quality of life (36-Item Short Form Health Survey), and adverse reactions before and after treatment were compared among the 3 groups. Multivariate logistic regression analysis was used to identify independent influencing factors for significant pain relief (defined as \u226550% reduction in VAS score). At baseline, disease duration, revised American Society for Reproductive Medicine stage and score, CA125 levels, and pain intensity in the DIE group were significantly higher than those in the OMA and SUP groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). After 6 months of treatment, pain VAS scores, lesion size, and CA125 levels significantly decreased from baseline in all 3 groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Intergroup comparisons showed statistically significant differences in the reduction of VAS scores (\u0394VAS) for dysmenorrhea and chronic pelvic pain (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.01), with the SUP group showing the smallest improvement. Meanwhile, the lesion reduction rate in the OMA group was significantly higher than that in the SUP and DIE groups (47.5% vs 39.4% vs 37.9%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Multivariate regression analysis showed that, compared with the OMA phenotype, the DIE phenotype was an independent negative predictor for significant pain relief (odds ratio\u2005=\u20050.67, 95% confidence interval: 0.43\u20130.99,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.046). DNG is significantly effective for all 3 endometriosis phenotypes, effectively relieving pain, reducing lesion size, and improving quality of life. However, patients with the DIE phenotype, due to the inherently more severe nature of their disease, have a relatively lower likelihood of achieving significant pain relief and a higher incidence of adverse reactions, necessitating special attention in clinical management.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047624","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:01:35Z","timestamp":1771005695000},"page":"e47624","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Differences in response to dienogest therapy among different phenotypes of endometriosis: A single-center retrospective cohort analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1655-5679","authenticated-orcid":false,"given":"Jixiao","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gynecology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin City, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin City, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin City, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260216","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMra1810764","article-title":"Endometriosis.","volume":"382","author":"Zondervan","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20260216","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/humrep\/des073","article-title":"The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres.","volume":"27","author":"Simoens","year":"2012","journal-title":"Hum Reprod"},{"key":"R3-20260216","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/jcm12030994","article-title":"Three types of endometriosis: pathogenesis, diagnosis and treatment. state of the art.","volume":"12","author":"Imperiale","year":"2023","journal-title":"J Clin Med"},{"key":"R4-20260216","doi-asserted-by":"crossref","first-page":"e8730","DOI":"10.7717\/peerj.8730","article-title":"Common and specific gene signatures among three different endometriosis subtypes.","volume":"8","author":"Jiang","year":"2020","journal-title":"PeerJ"},{"key":"R5-20260216","first-page":"88","article-title":"Management challenges of deep infiltrating endometriosis.","volume":"15","author":"D\u2019Alterio","year":"2021","journal-title":"Int J Fertil Steril"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/humrep\/der462","article-title":"Ovarian endometrioma: severe pelvic pain is associated with deeply infiltrating endometriosis.","volume":"27","author":"Chapron","year":"2012","journal-title":"Hum Reprod"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00404-015-3681-6","article-title":"Dienogest in the treatment of endometriosis: systematic review.","volume":"292","author":"Andres","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/IJWH.S77202","article-title":"Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program.","volume":"7","author":"Strowitzki","year":"2015","journal-title":"Int J Womens Health"},{"key":"R9-20260216","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.fertnstert.2015.08.031","article-title":"Treatment of pain associated with deep endometriosis: alternatives and evidence.","volume":"104","author":"Ferrero","year":"2015","journal-title":"Fertil Steril"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1440-1827.2003.01483.x","article-title":"Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis.","volume":"53","author":"Itoga","year":"2003","journal-title":"Pathol Int"},{"key":"R11-20260216","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5653\/cerm.2023.06128","article-title":"Dienogest in endometriosis treatment: a narrative literature review.","volume":"50","author":"Lee","year":"2023","journal-title":"Clin Exp Reprod Med"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"2402942","DOI":"10.1080\/07853890.2024.2402942","article-title":"Clinical efficacy of dienogest against endometriomas with a maximum diameter of \u22654 cm.","volume":"56","author":"Huang","year":"2024","journal-title":"Ann Med"},{"key":"R13-20260216","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/humupd\/dmae023","article-title":"The role of fibrosis in endometriosis: a systematic review.","volume":"30","author":"Vissers","year":"2024","journal-title":"Hum Reprod Update"},{"key":"R14-20260216","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.tjog.2024.04.009","article-title":"Dienogest treatment in women with endometriosis: a retrospective cohort study in Taiwan.","volume":"63","author":"Chen","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R15-20260216","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40360-024-00767-1","article-title":"A systematic review and Bayesian analysis of the adverse effects of dienogest.","volume":"25","author":"Li","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"R16-20260216","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/jcm9010154","article-title":"Long-term administration of dienogest for the treatment of pain and intestinal symptoms in patients with rectosigmoid endometriosis.","volume":"9","author":"Barra","year":"2020","journal-title":"J Clin Med"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"hoac009","DOI":"10.1093\/hropen\/hoac009","article-title":"ESHRE guideline: endometriosis.","volume":"2022","author":"Becker","year":"2022","journal-title":"Hum Reprod Open"},{"key":"R18-20260216","doi-asserted-by":"crossref","first-page":"1373582","DOI":"10.3389\/fphar.2024.1373582","article-title":"Dienogest in conjunction with GnRH-a for postoperative management of endometriosis.","volume":"15","author":"Ma","year":"2024","journal-title":"Front Pharmacol"},{"key":"R19-20260216","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.fertnstert.2016.12.024","article-title":"Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasinghormone agonist and add-back hormone therapy.","volume":"107","author":"Bedaiwy","year":"2017","journal-title":"Fertil Steril"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:02:55Z","timestamp":1771257775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047624","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-11-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}